Cutaneous lupus erythematosus induced by drugs - novel insights

References

• Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103:49–51.
   PubMed Web of Science ®Google Scholar
• Callen JP. Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol. 2001;45:315–316.
   PubMed Web of Science ®Google Scholar
• Lowe GC, Lowe G, Henderson CL, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164:465–472.
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4:253–263.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009;18:935–940.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Lazzari R, Polloni I, et al. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011;165:335–341.
   PubMed Web of Science ®Google Scholar
• Laurinaviciene R, Sandholdt LH, Bygum A. Drug-induced cutaneous lupus erythematosus: 88 new cases. Eur J Dermatol. 2017;27:28–33.
   PubMed Web of Science ®Google Scholar
• Guicciardi F, Atzori L, Marzano AV, et al. Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. J Am Acad Dermatol. 2019;81:403–411.
   PubMed Web of Science ®Google Scholar
• Grönhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167:296–305.
   PubMed Web of Science ®Google Scholar
• Lee LA, Roberts CM, Frank MB, et al. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol. 1994;130:1262–1268.
   PubMedGoogle Scholar
• Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139:45–49.
   PubMedGoogle Scholar
• Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010;19:1107–1111.
   PubMed Web of Science ®Google Scholar
• Sontheimer RD, Stastny P, Gilliam JN. Human histocompatibility antigen associations in subacute cutaneous lupus erythematosus. J Clin Invest. 1981;67:312–316.
   PubMed Web of Science ®Google Scholar
• Sontheimer RD, Maddison PJ, Reichlin M, et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med. 1982;97:664–671.
   PubMed Web of Science ®Google Scholar
• Jarrett P, Werth VP. A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach. J Multidiscip Healthc. 2019;12:419–428.
   PubMed Web of Science ®Google Scholar
• Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8:467–473.
   PubMed Web of Science ®Google Scholar
• Yoshimasu T, Hiroi A, Uede K, et al. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol. 2001;11:54–57.
   PubMed Web of Science ®Google Scholar
• Adachi A, Nagai H, Horikawa T. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. Dermatology. 2007;214:85–88.
   PubMed Web of Science ®Google Scholar
• Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2014;170:342–351.
   PubMed Web of Science ®Google Scholar
• Crowson AN, Magro CM. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol. 1997;28:67–73.
   PubMed Web of Science ®Google Scholar
• Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med. 1995;333:1429.
   PubMed Web of Science ®Google Scholar
• Cetkovská P, Pizinger K. Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil. Int J Dermatol. 2006;45:320–322.
   PubMed Web of Science ®Google Scholar
• Patri P, Nigro A, Rebora A. Lupus erythematosus-like eruption from captopril. Acta Derm Venereol. 1985;65:447–448.
   PubMed Web of Science ®Google Scholar
• Parodi A, Romagnoli M, Rebora A. Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide. Photodermatol. 1989;6:100–102.
   PubMedGoogle Scholar
• Capponi A, De Simone C, Guerriero C, et al. Ro/SSA-positive cutaneous lupus erythematosus induced by carbamazepine. Arch Dermatol. 2005;141:103–104.
   PubMedGoogle Scholar
• Amerio P, Innocente C, Feliciani C, et al. Drug-induced cutaneous lupus erythematosus after 5 years of treatment with carbamazepine. Eur J Dermatol. 2006;16:281–283.
   PubMed Web of Science ®Google Scholar
• Ross S, Ormerod AD, Roberts C, et al. Subacute cutaneous lupus erythematosus associated with phenytoin. Clin Exp Dermatol. 2002;27:474–476.
   PubMed Web of Science ®Google Scholar
• Jennings T, Ahmed S, Aphale A, et al. Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: an uncommon cause of drug-induced discoid lupus erythematosus. Australas J Dermatol. 2019;60:e208-e210.
   PubMed Web of Science ®Google Scholar
• Goodrich AL, Kohn SR. Hydrochlorothiazide-induced lupus erythematosus: a new variant? J Am Acad Dermatol. 1993;28:1001–1002.
   PubMed Web of Science ®Google Scholar
• Darken M, McBurney EI. Subacute cutaneous lupus erythematosus-like drug eruption due to combination diuretic hydrochlorothiazide and triamterene. J Am Acad Dermatol. 1988;18:38–42.
   PubMed Web of Science ®Google Scholar
• Brown CW, Deng JS. Thiazide diuretics induce cutaneous lupus-like adverse reaction. J Toxicol Clin Toxicol. 1995;33:729–733.
   PubMed Web of Science ®Google Scholar
• Fernández-Díaz ML, Herranz P, Suárez-Marrero MC, et al. Subacute cutaneous lupus erythematosus associated with cilazapril. Lancet. 1995;345:398.
   PubMed Web of Science ®Google Scholar
• Fenniche S, Dhaoui A, Ammar FB, et al. Acebutolol-induced subacute cutaneous lupus erythematosus. Skin Pharmacol Physiol. 2005;18:230–233.
   PubMed Web of Science ®Google Scholar
• Gubinelli E, Cocuroccia B, Girolomoni G. Subacute cutaneous lupus erythematosus induced by nifedipine. J Cutan Med Surg. 2003;7:243–246.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Borghi A, Mercogliano M, et al. Nitrendipine-induced subacute cutaneous lupus erythematosus. Eur J Dermatol. 2003;13:213–216.
   PubMed Web of Science ®Google Scholar
• Kurtis B, Larson MJ, Hoang MP, et al. Case report: verapamil-induced subacute cutaneous lupus erythematosus. J Drugs Dermatol. 2005;4:506–508.
   PubMedGoogle Scholar
• Kasperkiewicz M, Anemüller W, Angelova-Fischer I, et al. Subacute cutaneous lupus erythematosus associated with terbinafine. Clin Exp Dermatol. 2009;34:e403–4.
   PubMed Web of Science ®Google Scholar
• Brooke R, Coulson IH, al-Dawoud A. Terbinafine-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 1998;139:1132–1133.
   PubMed Web of Science ®Google Scholar
• Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212:59–65.
   PubMed Web of Science ®Google Scholar
• McKay DA, Schofield OM, Benton EC. Terbinafine-induced subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2004;84:472–474.
   PubMed Web of Science ®Google Scholar
• Bonsmann G, Schiller M, Luger TA, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2001;44:925–931.
   PubMed Web of Science ®Google Scholar
• Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. 2001;137:1196–1198.
   PubMedGoogle Scholar
• Miyagawa S, Okuchi T, Shiomi Y, et al. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol. 1989;21:343–346.
   PubMed Web of Science ®Google Scholar
• Noël B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatology. 2004;208:276–277.
   PubMed Web of Science ®Google Scholar
• Crowson AN, Magro CM. Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy. J Cutan Pathol. 1999;26:95–99.
   PubMed Web of Science ®Google Scholar
• Toll A, Campo-Pisa P, González-Castro J, et al. Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy. Lupus. 1998;7:364–366.
   PubMed Web of Science ®Google Scholar
• Newman AJ, Mullens D, Lin CC, et al. Subacute cutaneous lupus erythematosus observed with ciprofloxacin. BMJ Case Rep. 2018;11:e227707.
   PubMedGoogle Scholar
• Parodi A, Rivara G, Guarrera M. Possible naproxen-induced relapse of subacute cutaneous lupus erythematosus. JAMA. 1992;268:51–52.
   PubMed Web of Science ®Google Scholar
• Roura M, Lopez-Gil F, Umbert P. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica. 1991;182:56–58.
   PubMedGoogle Scholar
• Mayor-Ibarguren A, Roldán-Puchalt MC, Gómez-Fernández C, et al. Subacute cutaneous lupus erythematosus induced by mitotane. JAMA Dermatol. 2016;152:109–111.
   PubMed Web of Science ®Google Scholar
• Wilkerson E, Hazey MA, Bahrami S, et al. Golimumab-exacerbated subacute cutaneous lupus erythematosus. Arch Dermatol. 2012;148:1186–1190.
   PubMedGoogle Scholar
• Brunasso AM, Aberer W, Massone C. Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis. Lupus. 2014;23:201–203.
   PubMed Web of Science ®Google Scholar
• Stratigos AJ, Antoniou C, Stamathioudaki S, et al. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004;29:150–153.
   PubMed Web of Science ®Google Scholar
• Cemil BC, Atas H, Canpolat F, et al. Infliximab-induced discoid lupus erythematosus. Lupus. 2013;22:515–518.
   PubMed Web of Science ®Google Scholar
• Bentley DD, Graves JE, Smith DI, et al. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006;54:S242–3.
   PubMed Web of Science ®Google Scholar
• Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol. 2005;46:266–269.
   PubMedGoogle Scholar
• Hannah CE, Little AJ, Wanat KA, et al. Drug-induced cutaneous lupus erythematosus: a case series of five patients with bupropion-associated disease. J Clin Rheumatol. 2018. [Epub ahead of print]
   PubMedGoogle Scholar
• Trancart M, Cavailhes A, Balme B, et al. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2008;158:628–629.
   PubMed Web of Science ®Google Scholar
• Fisher J, Patel M, Miller M, et al. Anastrozole-induced subacute cutaneous lupus erythematosus. Cutis. 2016;98:E22–6.
   PubMed Web of Science ®Google Scholar
• Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet. 1998;352:1825–1826.
   PubMed Web of Science ®Google Scholar
• Adrichem ME, Starink MV, van Leeuwen EMM, et al. Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. J Peripher Nerv Syst. 2017;22:213–218.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Ramoni S, Del Papa N, et al. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus. 2008;17:329–331.
   PubMed Web of Science ®Google Scholar
• Kerr OA, Murray CS, Tidman MJ. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol. 2004;29:319–320.
   PubMed Web of Science ®Google Scholar
• Gensburger D, Kawashima M, Marotte H, et al. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis. 2005;64:153–155.
   PubMed Web of Science ®Google Scholar
• Goëb V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2005;44:823–824.
   PubMed Web of Science ®Google Scholar
• Wiechert A, Tüting T, Bieber T, et al. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol. 2008;159:231–233.
   PubMed Web of Science ®Google Scholar
• Reich A, Bialynicki-Birula R, Szepietowski JC. Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine. Int J Dermatol. 2006;45:1112–1114.
   PubMed Web of Science ®Google Scholar
• Pham HC, Saurat JH. Inhalation route inducing subacute cutaneous lupus erythematosus with tiotropium. Arch Dermatol. 2005;141:911–912.
   PubMedGoogle Scholar
• Bracke A, Nijsten T, Vandermaesen J, et al. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol. 2005;85:353–354.
   PubMed Web of Science ®Google Scholar
• He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30:490–497.
   PubMed Web of Science ®Google Scholar
• Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002–2009. PLoS One. 2013;8:e56060.
   PubMed Web of Science ®Google Scholar
• Michaelis TC, Sontheimer RD, Lowe GC. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J. 2017;23.
   Google Scholar
• Sheth N, Greenblatt D, Patel S, et al. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol. 2007;32:593–594.
   PubMed Web of Science ®Google Scholar
• Bleumink GS, Ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40:1317–1319.
   PubMed Web of Science ®Google Scholar
• Quaresma MV, Bernardes Filho F, Oliveira FB, et al. Anti-TNF-α and hydralazine drug-induced lupus. An Bras Dermatol. 2015;90:125–129.
   PubMed Web of Science ®Google Scholar
• Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011;50:619–625.
   PubMed Web of Science ®Google Scholar
• Stein JE, Patterson-Fortin J, Bodnar BE. Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis. BMJ Case Rep. 2018;2018.
   Google Scholar
• Tarazi M, Aiempanakit K, Werth VP. Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. JAAD Case Rep. 2018;4:698–700.
   PubMedGoogle Scholar
• Tierney E, Kirthi S, Ramsay B, et al. Ustekinumab-induced subacute cutaneous lupus. JAAD Case Rep. 2019;5:271–273.
   PubMedGoogle Scholar
• Wehrmann C, Sondermann W, Körber A. [Secukinumab-induced subacute-cutaneous lupus erythematosus]. Hautarzt. 2018;69:64–66.
   PubMed Web of Science ®Google Scholar
• Romero-Maté A, García-Donoso C, Hernández-Núñez A, et al. Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab. Dermatol Online J. 2017;23.
   Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392:1330–1339.
   PubMed Web of Science ®Google Scholar
• Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol. 2010;146:1113–1116.
   PubMedGoogle Scholar
• Guhl G, Diaz-Ley B, García-García C, et al. Chemotherapy-induced subacute lupus erythematosus. Lupus. 2009;18:859–860.
   PubMed Web of Science ®Google Scholar
• Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004;31:818–820.
   PubMed Web of Science ®Google Scholar
• Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol. 2007;34:473–476.
   PubMed Web of Science ®Google Scholar
• Weger W, Kränke B, Gerger A, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol. 2008;59:S4–6.
   PubMed Web of Science ®Google Scholar
• Fernandes NF, Rosenbach M, Elenitsas R, et al. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Arch Dermatol. 2009;145:340–341.
   PubMedGoogle Scholar
• Cornacchia MA, Coromilas AJ, Gallitano SM, et al. Subacute cutaneous lupus erythematosus induced by gemcitabine in 2 patients with pancreatic cancer. JAAD Case Rep. 2019;5:596–601.
   PubMedGoogle Scholar
• Nieto-Rodríguez D, Gómez-Fernández C, Rueda-Carnero JM, et al. Subacute cutaneous lupus erythematosus induced by masitinib. Int J Dermatol. 2017;56:1180–1181.
   PubMed Web of Science ®Google Scholar
• Liu RC, Sebaratnam DF, Jackett L, et al. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J Dermatol. 2018;59:e152–e4.
   PubMed Web of Science ®Google Scholar
• Zitouni NB, Arnault JP, Dadban A, et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019;29:212–215.
   PubMed Web of Science ®Google Scholar
• Pinard J, Patel M, Granter SR, et al. Subacute cutaneous lupus erythematosus induced by palbociclib. J Cutan Med Surg. 2018;22:341–343.
   PubMed Web of Science ®Google Scholar
• Shao K, McGettigan S, Elenitsas R, et al. Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy. J Cutan Pathol. 2018;45:74–77.
   PubMed Web of Science ®Google Scholar
• Fumal I, Danchin A, Cosserat F, et al. Subacute cutaneous lupus erythematosus associated with tamoxifen therapy: two cases. Dermatology. 2005;210:251–252.
   PubMed Web of Science ®Google Scholar
• Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol. 2016;17:135–146.
   PubMed Web of Science ®Google Scholar
• Chen KL, Krain RL, Werth VP. Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. F1000Res. 2019;8.
   PubMedGoogle Scholar
• Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73:326–334.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533.
   PubMed Web of Science ®Google Scholar
• Dorgham K, Amoura Z, Parizot C, et al. Ultraviolet light converts propranolol, a nonselective β-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. Eur J Immunol. 2015;45:3174–3187.
   PubMed Web of Science ®Google Scholar
• Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science. 1994;266:810–813.
   PubMed Web of Science ®Google Scholar
• Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest. 1995;73:746–759.
   PubMed Web of Science ®Google Scholar
• Yung RL, Quddus J, Chrisp CE, et al. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol. 1995;154:3025–3035.
   PubMed Web of Science ®Google Scholar
• Yung R, Chang S, Hemati N, et al. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum. 1997;40:1436–1443.
   PubMed Web of Science ®Google Scholar
• Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45:344–355.
   PubMed Web of Science ®Google Scholar
• Irizarry-Caro JA, Carmona-Rivera C, Schwartz DM, et al. Brief report: drugs implicated in systemic autoimmunity modulate neutrophil extracellular trap formation. Arthritis Rheumatol. 2018;70:468–474.
   PubMed Web of Science ®Google Scholar
• Alves P, Bashir MM, Wysocka M, et al. Quinacrine suppresses tumor necrosis factor-α and IFN-α in dermatomyositis and cutaneous lupus erythematosus. J Investig Dermatol Symp Proc. 2017;18:S57–S63.
   PubMedGoogle Scholar
• Via CS, Shustov A, Rus V, et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001;167:6821–6826.
   PubMed Web of Science ®Google Scholar
• Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84:979–984.
   PubMed Web of Science ®Google Scholar
• Chasset F, Francès C. Current concepts and future approaches in the treatment of cutaneous lupus erythematosus: a comprehensive review. Drugs. 2019;79:1199–1215.
   PubMed Web of Science ®Google Scholar
• Jessop S, Whitelaw DA, Grainge MJ, et al. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2017;5:CD002954.
   PubMedGoogle Scholar
• Barikbin B, Givrad S, Yousefi M, et al. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34:776–780.
   PubMed Web of Science ®Google Scholar
• Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27:391–404.
   PubMed Web of Science ®Google Scholar
• Wozniacka A, McCauliffe DP. Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol. 2005;6:1–11.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31:389–404.
   PubMed Web of Science ®Google Scholar